Figure 4.

Greater breadth of IgG binding to SARS-CoV-2 variant RBDs following vaccination with four different vaccines compared with infection with Wuhan-Hu-1 SARS-CoV-2

Anti-SARS-CoV-2 Wuhan-Hu-1 and viral variant RBD IgG responses are shown for individuals who received BNT162b2 (BioNTech-Pfizer), ChAdOx1-S (Astra Zeneca), Gam-COVID-Vac (Sputnik V), and BBIBP-CorV (Sinopharm) vaccination and for Wuhan-Hu-1-infected COVID-19 Stanford patient cohort 2 within 1 month and around 3 months after vaccination/COVID-19 symptom onset. Box-whisker plots show the interquartile range as the box and the whisker ends as the most extreme values within 1.5 times the interquartile range below the 25% quantile and above the 75% quantile. Significance between groups was tested with pairwise Wilcoxon rank sum test with Bonferroni correction. ^∗p < 0.05, ^∗∗p < 0.01, ^∗∗∗p < 0.001

(A) Anti-RBD IgG concentrations.

(B) Ratios of anti-Wuhan-Hu-1 to variant RBD IgG concentration.